Aquestive Therapeutics Expands Global Reach for Anaphylm™
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is making significant strides in enhancing its global footprint with the development of Anaphylm™ (epinephrine) Sublingual Film. As the company addresses the urgent need for effective treatments, it recently secured a meeting with Health Canada to discuss its New Drug Submission (NDS), which is projected for the third quarter of 2025. This step aligns with the company's commitment to bringing innovative solutions to patients worldwide.
Initial Regulatory Steps in Canada and Europe
In a proactive move, Aquestive has submitted an initial briefing book to the European Medicines Agency (EMA), which marks an essential milestone in its regulatory journey. The company is also preparing to file a Marketing Authorization Application (MAA) to the EMA in the near future, which will further solidify its position in the European market.
Innovative Treatment Options
At the heart of Aquestive's mission is the innovative Anaphylm™ product. Unlike conventional epinephrine auto-injectors that rely on needles, Anaphylm™ is designed to be administered orally, effectively addressing common obstacles such as needle phobia and the complexities associated with traditional delivery devices. Its compact size, similar to a postage stamp, enhances portability, empowering patients with a reliable alternative to manage severe allergic reactions quickly.
A Strategic Global Regulatory Approach
“These regulatory activities form the foundational elements of our comprehensive strategy for international expansion,” stated Dan Barber, President and Chief Executive Officer of Aquestive. With the recent acceptance of their U.S. FDA New Drug Application and a PDUFA target action date set for early 2026, the company is uniquely positioned to pursue regulatory pathways that could greatly benefit underserved patients.
Aquestive's strategy involves focusing on international markets with substantial unmet medical needs. The collaborative regulatory environments in Canada and Europe make them ideal candidates for the initial rollout of Anaphylm™, where a significant patient population requires dependable anaphylaxis treatment options.
Commitment to Global Health Improvement
Aquestive’s expertise in navigating regulatory landscapes and its proven track record illustrate its capacity to efficiently secure international approvals. With six FDA-approved drugs in its portfolio and a presence across six continents, the company aims to set a new standard in treating severe allergic reactions.
About Anaphylm™ (epinephrine) Sublingual Film
Anaphylm™ is a cutting-edge polymer matrix-based epinephrine prodrug that weighs less than an ounce and dissolves upon contact, eliminating the need for water or swallowing. Its packaging is not only portable but also resilient against diverse environmental conditions, making it an excellent choice for patients on the go.
About Aquestive Therapeutics
Aquestive is dedicated to enhancing patients' lives through innovative pharmaceutical solutions. With a focus on developing orally administered products, the company offers alternatives to conventional treatments. Currently, it boasts four commercialized products marketed globally and continues to collaborate with industry partners to unleash new molecules using its proprietary technologies.
As it advances Anaphylm™, Aquestive is also exploring additional potential treatments, including a topical gel for dermatological conditions. The company's commitment to addressing significant medical needs continues to drive its innovative pipeline.
Frequently Asked Questions
What is Anaphylm™?
Anaphylm™ is an oral epinephrine product designed to treat severe allergic reactions and anaphylaxis, providing a needle-free delivery option.
When will Anaphylm™ be available in Canada?
The New Drug Submission for Anaphylm™ is scheduled for discussion with Health Canada in the third quarter of 2025.
How does Anaphylm™ differ from traditional epinephrine auto-injectors?
Anaphylm™ avoids the use of needles, offering oral administration to eliminate complications like needle phobia and device malfunctions.
What is the significance of the EMA submission?
The submission to the EMA is part of a strategy to secure regulatory approval in Europe, expanding access to effective allergy treatments.
What is the future outlook for Aquestive Therapeutics?
Aquestive is committed to advancing its innovative pipeline and will continue to update on its global regulatory progress and new treatment options.
